New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
09:23 EDTHPTXHyperion Therapeutics should be bought on any weakness, says JMP Securities
After sales of Hyperion's Ravicti beat expectations in Q2 but the company disclosed a delay in the initiation of its planned Phase 3 hepatic encephalopathy program for Ravicti, JMP Securities thinks any weakness in the stock is a buying opportunity for investors with a long-term focus, and/or an appreciation for the potential value of the company's diabetes program. The firm notes that Phase 3 data for the drug is expected in 1Q15 and keeps an Outperform rating.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
09:12 EDTHPTXHyperion Therapeutics has reached attractive entry point, says Roth Capital
Roth Capital believes that Hyperion is back in favor with investors, given the 11% increase in its stock so far this year. However, the firm notes that the company's valuation is still below the average of its peer group. Roth thinks the company has a number of near-term positive catalysts, and it keeps a Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use